|Bid||15.28 x 100|
|Ask||23.79 x 300|
|Day's Range||20.09 - 20.65|
|52 Week Range||15.15 - 35.35|
|PE Ratio (TTM)||43.40|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||19.89|
Molecular diagnostics and personalized medicine major Myriad Genetics, Inc. (MYGN) recently received extended Medicare coverage for its Prolasis test.
SALT LAKE CITY, May 25, 2017-- Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced that Palmetto GBA, a Medicare Administrative Contractor that assesses ...
Q3 2017 Myriad Genetics Inc Earnings Call